drugset / Trial / NCT02156492

A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants

NCT02156492

Phase 1 Completed 62 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to investigate how the body responds to evacetrapib and to evaluate the safety and the effect of evacetrapib, alone and in combination with selected statins, in healthy Chinese participants. The study has 2 parts. Part one will last up to 4 weeks and part two will last up to 5 weeks, not including screening. Participants may only enroll in one part.

Timeline

Start
2014-06
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule Oral
Subject Evacetrapib Small molecule 130 mg Oral
Subject Simvastatin Small molecule Oral

Indications

No indication recorded.